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Abstract 
Background: Novel tuberculosis (TB) vaccines that aim to boost and/or replace Bacillus Calmette-Guerin (BCG) 
are currently in development. DNA vaccines can stimulate both humoral and cell-mediated immunity in different 
animal models of TB and is thought to be a promising strategy in the development of new vaccines against TB. The 
aim of this study was to design and construct a DNA vaccine encoding ag85a and tb10.4 fusion genes of 
Mycobacterium tuberculosis.  
Materials and Methods: tb10.4 fragment was amplified by PCR and the product was digested with restriction 
enzymes. Next, it was cloned into the pcDNA3.1+ plasmid. The ag85a gene and pcDNA3.1+/tb10.4 plasmid were 
digested by EcoRI and BamHI restriction enzymes. Constructed vector was sequenced. The molecular analysis was 
done using bioinformatics software. New chimeric vector containing ag85a-tb10.4 genes were purified. Expression 
of pcDNA3.1+/tb10.4-ag85a plasmid was confirmed in eukaryotic cells.   
Results: Fragments of 297 bp for tb10.4 and 1017 bp for ag85a were observed in agarose gel electrophoresis. 
Alignment of ag85a-tb10.4 genome sequence with reference genes in GenBank showed exact identities that indicate 
correction of all cloning procedures.  Transfection of eukaryotic cells with pcDNA3.1+/tb10.4-ag85a vector and 
existence of tb10.4-ag85a fusion gene were both confirmed with RT-PCR.  
Conclusion: In this study, tb10.4 and ag85a genes were isolated from Mycobacterium tuberculosis H37Rv strain 
and cloned into pcDNA3.1+. Also, the capability of constructed vector in producing fusion ag85a-tb10.4 protein was 
confirmed with RT-PCR. pcDNA3.1+/tb10.4-ag85a vector can be used for further studies in future.   
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In 1882, Robert Koch, identified 
Mycobacterium tuberculosis (M. tuberculosis) as the 
cause of tuberculosis (TB) (1-3). TB is one of the 
important causes of worldwide death, with an 
estimated 9.4 million new cases and 1.7 million 
deaths in 2008 (4, 5).  
Mycobacterium bovis bacillus Calmette–
Guérin (BCG), the only licensed TB vaccine, is a live 
attenuated strain of M. bovis which was passaged by 
Calmette and Guérin almost one hundred years ago. 
BCG confers resistance to meningitis caused by M. 
tuberculosis and the disseminated form of TB among 
children (4, 6, 7). On the other hand; it confers a 
highly variable protection against pulmonary disease 
in adults. This is the major reason for the high 
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morbidity and mortality among the TB-infected 
patients (4, 8). 
The limited effectiveness of BCG vaccine 
against tuberculosis has led scientists to the 
development of a more effective vaccine such as 
plasmid DNA vaccines encoding the dominant genes 
of M. tuberculosis (9-11). 
DNA vaccines induce protective immunity in 
several animal models of parasitic, viral and bacterial 
infections. DNA vaccines have advantages over other 
vaccines. These include the easy procedure to 
produce, stability, and safely used for 
immunocompromised patients (12-15). 
An understanding of the nature of protective 
immunity is required to design an effective vaccine 
against TB. A cellular immune response is an 
essential requirement for protective immunity against 
mycobacterial diseases, and all new TB vaccines are 
supposed to induce high levels of cellular immunity. 
CD4+ T cells, together with the Th-1 cytokines, 
interferon gamma (IFNγ) and tumor necrosis factor 
alpha (TNFα) are necessary for protective immunity 
(4, 16). CD8+ T cells are probably also required for 
optimal protective immunity (4, 17). 
Several immunogenic secreted antigens have 
been identified using advanced molecular 
technologies (18). An important part of secretory 
proteins is formed by Ag85 complex; a family of 
three proteins (Ag85A, Ag85B, Ag85C). All three 
proteins have mycolyl transferase enzyme activity. 
These fibronectin-binding proteins are responsible 
for binding to human macrophages during the early 
phase of infection (19, 20). 
tb10.4 gene belongs to ESAT-6 family that 
encodes three highly homologous proteins (TB10.4 
(Rv0288), TB10.3 (Rv3019c) and TB12.9 
(Rv3017c)). These members of TB10.4 family are 
present only in strains of M. tuberculosis complex 
(1). 
The aim of the present study was to clone 
tb10.4 and ag85a genes in pcDNA3.1+ plasmid and 
transfection of eukaryotic cells by 
pcDNA3.1+/tb10.4-ag85a recombinant plasmid. 
Methods 
DNA extraction. DNA extraction from 
Mycobacterium tuberculosis H37Rv strain was 
performed as described previously; briefly, 
Mycobacterium tuberculosis H37Rv strain was 
cultured on Lowenstain medium and then, grown 
colony diluted in buffer (Tris- Cl (100 mM, pH = 7.5), 
Tween-20 (0.05%)) and DNA extraction performed 
based on boiling method as described previously (21).   
Amplification and cloning of tb10.4 fragment. 
Specific primers for isolation of tb10.4 were designed 
using GeneRunner software. tb10.4 fragment 
amplification was performed by PCR then, it was 
cloned into pcDNA3.1+ plasmid as described 
previously (21). 
Ag85a gel purification and enzyme digestion. 
First, terminal sequence of ag85a was deleted from the 
end of the gene. In next step, two restriction enzymes 
(BamHI and EcoRI) which did not have restriction 
sites inside the gene were selected using gene runner 
software. Then, full length sequence of ag85a flanked 
by these two restriction sites and a kozak sequence at 
the 3´ end was designed and synthesized by GENEray 
(China). The synthetic gene cloned into pUC57 and 
the plasmid were digested with BamHI and EcoRI 
restriction enzymes (Fermentas, Germany). Then, 
digested plasmid was purified from the gel and ligated 
into the digested and purified pcDNA3.1+/tb10.4 
plasmid. 
ag85a cloning confirmation in 
pcDNA3.1+/tb10.4 vector. pcDNA3.1+/ag85a-tb10.4 
construct was used for transformation by heat shock 
method (22). Transformed bacteria were inoculated on 
LB agar medium containing 100 g/ml ampicillin for 
16 hour at 37°C.  Cloning of ag85a into 
pcDNA3.1+/tb10.4 was confirmed by colony-PCR 
method using forward primer of ag85a fragment and 
reverse primer of tb10.4 fragment and enzymatic 
digestion with EcoRI and BamHI enzymes. 
Colonies were screened by colony-PCR. PCR 
reaction mixture contained 0.5μl dNTP (0.2mM), 
0.3μl Taq DNA polymerase (5U/μl), 1.5μl MgCl2 
(1.5mM), 2.5μl Buffer 10X (Fermentas, Germany), 
17.2μl DNase free water, 1μl Forward primer of ag85a 
(5'AATATAGGATCCACCATGGGACAGCTTGTT
GACAGGGTTCGTGGC–3') (10 pmol) and 1μl 
Reverse primer of tb10.4 
(5'ACTATATCTAGATTACTAACCTCCCCATTTG
GCG –3') (10 pmol) (CinnaGen, Iran).  
The following Colony-PCR program for ag85a 
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was used: First cycle at 95°C for 300 seconds  
followed by 40 subsequent cycles of 95°C for 60 
seconds, 52°C for 60 seconds, 72°C for 60 seconds 
and final extension of  72°C for 420 seconds. 
Expression in eukaryotic system. 
pcDNA3.1+/ag85a-tb10.4 was purified with alkaline 
method and transfected in eukaryotic HeLa cells that 
was cultured in DMEM medium containing 10% 
FBS (Fetal Bovine Serum) and 1% antibiotics 
(penicillin and streptomycin) using cationic liposome 
method (23). In this method, the complex contains 
pcDNA3.1+/ag85a-tb10.4, lipofectamine and DMEM 
medium without FBS and antibiotics. The culture 
was incubated for 24h in 37°C with 5% CO2. Then, 
the medium was exchanged with DMEM containing 
FBS and antibiotics.   
RNA extraction. To confirm tb10.4-ag85a 
gene expression in eukaryotic cells, the cells were 
collected 48 hours after transfection. Next, RNA 
extraction was performed with RNX-PLUS kit 
(CinnaGen, Iran) as described previously (21). 
RT-PCR for confirming the expression. RT-
PCR was performed with the RNA extract and oligo 
dT (used as a primer) and DEPC- treated water free 
RNA enzyme in an RNase free microtube. After 
addition of pre-mixed solution containing RNase 
inhibitor and thermos-resistant RT, the microtube 
was incubated at 70°C for 10 min. 
In the final stage, to confirm the expression of 
tb10.4-ag85a fragment, we have done PCR. Forward 
primer of ag85a and reverse primer of tb10.4 were 
used for this reaction. 
Sequencing. For the final confirmation, 
recombinant vector containing tb10.4-ag85a genes 
was sequenced with the universal primers T7 and 
BGH MacroGen, Korea) 
Results 
Extracted DNA was used for PCR reactions. 
Then, the PCR products were electrophoresized on a 
1.5% agarose gel.  290 bp amplified fragment of 
tb10.4 (Figure 1) and 1017 bp fragment of ag85a 
gene were observed (Figure 2). 
After enzyme digestion and purification of 
ag85a fragment, it was ligated to a 
pcDNA3.1+/tb10.4 recombinant vector and then 
pcDNA3.1+/ag85a-tb10.4 recombinant vector was 
transformed to a competent E. coli JM109 strain.  
16h after transformation of competent bacteria 
at 37°C, some colonies were grown on LB agar 
medium containing ampicillin. The 
pcDNA3.1+/tb10.4/ag85a was confirmed by colony-
PCR using forward primer of ag85a and reverse 
primer of tb10.4. Colonies with the specific plasmid 
 
 
Figure 1. Purified PCR product of tb10.4 gene on 1.5% gel: Lane 1: 




Figure 2. Purified PCR product of ag85a gene on 1.5% gel: Lane 1: 
1017 bp band of ag85a , Lane 2: 1kb DNA size marker (SM0313, 
Fermentas, Germany). 
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were positive and showed the corresponding 1300bp 
lane compared to 1kp DNA size marker (Figure 3). 
 
Digestion was performed using EcoRI and 
BamHI restriction enzymes. 1300 bp fragment of 
tb10.4/ag85a was observed (Figure 4). 
Sequence analysis of tb10.4-ag85a genes 
showed that there is 100% identity between acquired 
sequence and registered sequences in Gene Bank. 
These data confirm all cloning procedures. 
HeLa eukaryotic cells (grown in DMEM culture 
medium) were transfected with PcDNA3.1+/tb10.4-
ag85a recombinant vector and cells for 48h at 37°C. 
Finally, to confirm the expression of this gene in 
eukaryotic cells, RNA extraction, cDNA synthesis and 
RT-PCR (using tb10.4 reverse primer and ag85a 
forward primer) was performed respectively, and a 
1300 bp fragment of tb10.4/ag85a was observed 
(Figure 5). 
Discussion 
The strategy of developing vaccines which 
confer cellular immunity toward the pathogen results 
in the increase in the number of specific T-cells for the 
pathogen. In the case of tuberculosis, there are no 
biomarkers of protective immunity and consequently a 
better understanding of what constitutes a protective T 
cell response could more effectively guide vaccine 
development (24). 
Novel TB vaccines that aim to boost and/or 
replace BCG are currently in development and some 
have shown promising results in in vitro studies, 
animal models, and phase I and II clinical trials (25). 
DNA vaccines can stimulate both humoral and 
cell-mediated immunity in different animal models of 
 
 
Figure 3. Colony-PCR results. Lane 1: 1kb DNA size marker 





Figure 4. Restriction enzyme digestion of pcDNA3.1+/ag85a-
tb10.4. Lane 1: 1kb DNA size marker (SM0313, Fermentas, 




Figure 5. RT-PCR results. Lane 1: 1300 bp band of ag85a/tb10.4; 
Lane 2: 1kb DNA size marker (SM0313, Fermentas, Germany). 
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TB and is thought to be a promising strategy in the 
development of new vaccines against it. DNA 
vaccine candidates expressing several antigens of M. 
tuberculosis have been shown to provide protective 
immune responses against TB (26). 
When complete genome sequence of M. 
tuberculosis was identified, more than 100 subunit 
and DNA vaccines have been studied. However, still 
no protective antigen of M. tuberculosis has been 
found for vaccine development purposes and this has 
created a major barrier in the development of TB 
vaccines. To date, only a few DNA vaccine encoding 
ag85a, ag85b, esat-6, Pst-3 and hsp65 have shown 
promising degree of protection (27). 
Subunit vaccines comprise a small set of 
secreted antigens, i.e., proteins secreted by 
metabolically active M. tuberculosis. The frequently 
used Ag85 cognates, ag85a or ag85b, which are most 
widely used in the current vaccine candidates are 
shared by BCG and M. tuberculosis. Additional 
antigens that are unique to M. tuberculosis are 
ESAT6 and tb10.4. They  (ESAT6 and tb10.4) are 
encoded within the region of difference 1 (RD-1) 
gene cluster which is present in M. tuberculosis and 
absent in BCG (28). 
In the present study, in order to produce a 
vaccine against M. tuberculosis strain H37Rv, tb10.4 
and ag85a antigens were used. The antigen 85 
complex is composed of at least three different 
closely related proteins named 85A, 85B, and 85C 
and is a major secretion product of several 
mycobacterial species with a MW range of 30–32000 
daltons. These proteins are also found associated 
with the bacterial cell surface. Their properties, 
especially the capacity to bind fibronectin, in 
addition to the surface association, make them an 
attractive virulence factor candidates (29). 
Sushila D’Souza study indicated that 
vaccination with plasmid DNA encoding M. 
tuberculosis ag85a was immunogenic and could 
protect mice against an aerosol and M. tuberculosis 
challenge infection (10, 30). 
Esat-6 gene family (such as tb10.4), has 
attracted significant interest and has been 
demonstrated to encode several immunodominant 
molecules that are strongly recognized by the 
immune systems in different animal models of TB, as 
well as by T cells from human beings exposed to M. 
tuberculosis (1). 
In this study, restriction enzymes EcoRI and 
XbaI were used to clone tb10.4. Transformation was 
performed using E. coli strain JM109. Eukaryotic cells 
were transfected with PcDNA3.1+ vector. To confirm 
the expression in eukaryotic cells, RNA extraction, 
RT-PCR and cDNA synthesis was performed. 
Ag85a and tb10.4 are strongly recognized by T-
cells isolated from TB patients and have been 
observed to induce a robust cell mediated immune 
response (31). 
Gilson C. Macedo et al showed the ability of 
Ag85A, Ag85B, and ESAT-6 to differentiate TB 
patients from controls (32). 
Jia Lu et al showed that two DNA vaccine 
separately encoding antigen Ag85A and ESAT-6 
could induce strong humoral and cell-mediated 
immunity in vaccinated mice which resulted in some 
degree of protection in mice challenged with virulent 
M. tuberculosis (26, 27). 
Vaccination has a major role in the final goal of 
global eradication of tuberculosis (33). In this study, 
ag85a and tb10.4 genes of M. tuberculosis with the use 
of pcDNA3.1+ plasmid were fused. Then, eukaryotic 
cells were transfected with pcDNA3.1+/tb10.4-ag85a 
plasmid for confirming expression of tb10.4-ag85a in 
these cells. This study can be used for development of 
more new DNA vaccines in future studies.  
Conclusion 
The risk of increasing spread of TB and 
development of drug resistance make treatment a 
matter of greatest concern. In this study, a DNA 
vaccine encoding ag85a and tb10.4 fragments was 
prepared. Successful cloning provides a basis for 
development of new DNA vaccines against 
tuberculosis. The designed expression vector can be 
used as a DNA vaccine in future studies. In addition, it 
can be administered with other TB vaccines in animal 
models. 
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